LONDON (Reuters) - European Union regulators have recommended Pfizer's new genetically targeted lung cancer drug Xalkori for approval, following marketing approval for the medicine in the United States last August. The U.S. drugmaker said on Friday the European Medicines Agency had recommended the medicine for conditional authorization, which means Pfizer will need to submit further data from a recent successfully completed clinical trial. Recommendations for drug approvals by the EMA are normally formally endorsed by the European Commission within months. ...
via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment